SULFHYDRYL MODIFIED HYALURONIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
20230022581 · 2023-01-26
Inventors
Cpc classification
Y02P20/55
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
C08B37/0072
CHEMISTRY; METALLURGY
International classification
Abstract
A sulfhydryl modified hyaluronic acid has a high mercaptan content, and a small change in the molecular mass of the main chain molecule, and has a significantly improved viscosity, water retention, and oxidation resistance. It is prepared from hyaluronic acid modified by acryl-based compounds and polysulfhydryl compounds by means of the Michael addition reaction of mercaptan and conjugated double bonds. The preparation method can flexibly control the structure and composition of a synthesized product, the type and content of the terminal functional group of a large number of compound molecules, etc. The use of a reagent having high biocompatibility effectively controls the production cost and reduces the toxicity during the synthesis.
Claims
1. A sulfhydryl-modified hyaluronic acid compound, characterized in that, part or all of —COOH and/or —OH comprised in a side chain of a repeating unit of the hyaluronic acid are modified to form a side chain with the following terminal group: ##STR00045## in the above group, * represents a linking site; R.sub.1 is selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; R.sub.2 and R.sub.3 are the same or different and are independently selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; and R.sub.4 is a fragment of a polysulfhydryl compound.
2. The sulfhydryl-modified hyaluronic acid compound according to claim 1, characterized in that, the terminal group is linked to the —COOH and/or the —OH through an R group or directly to the —COOH and/or the —OH to form a side chain of at least one of the following structures: ##STR00046## in the structures a, b, c and d, R is selected from ##STR00047## hydrocarbylene, arylene, an amide residue, a hydrazide residue, and the like; * represents a linking site; 1* represents a linking site to a left-hand group of R; 2* represents a linking site to a right-hand group of R; R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above.
3. The sulfhydryl-modified hyaluronic acid compound according to claim 1, characterized in that, the sulfhydryl-modified hyaluronic acid comprises at least one of the following structures: ##STR00048## wherein in the above structures, R, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above; (n2+n3)/(n1+n2+n3) represents a degree of acryloylation; n3/(n1+n2+n3) represents a degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method; the n1 can be 0, and if it is 0, the degree of acryloylation is not limited, and n3/(n2+n3) alone represents the degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method; the n2 can be 0, and if it is 0, n3/(n1+n3) represents both the degree of acryloylation and the degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method; the A.sub.1 is: ##STR00049## the A.sub.2 is one of the following structures: ##STR00050## * in the structure of A.sub.1 and A.sub.2 represents a linking site to the COOH or the OH.
4. The sulfhydryl-modified hyaluronic acid compound according to claim 1, characterized in that, R.sub.4 is a fragment of a polysulfhydryl compound, that is, an —S—R.sub.4—SH fragment can be introduced from polysulfhydryl compounds including but not limited to the following: ##STR00051## wherein n4 is an integer from 2 to 30, such as 2, 3, 4, 5 or 6 etc.; n5 is an integer from 1 to 30, such as 1, 2, 3, 4 or 5 etc.; n6 is an integer from 1 to 30, such as 1, 2, 3, 4 or 5 etc.; 4-arm-PEG-SH represents a PEG polymer containing four sulfhydryl groups; 6-arm-PEG-SH represents a PEG polymer containing six sulfhydryl groups; 8-arm-PEG-SH represents a PEG polymer containing eight sulfhydryl groups; the PEG is an abbreviation for polyethylene glycol.
5. The sulfhydryl-modified hyaluronic acid compound according to claim 1, characterized in that, the sulfhydryl-modified hyaluronic acid has at least one of the following structures: ##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086## in the above structural formulas, n.sub.1, n.sub.2 and n.sub.3 are defined as above.
6. A preparation method for the sulfhydryl-modified hyaluronic acid according to claim 1, characterized in that, the method comprises the following steps: 1) acryloylating the hyaluronic acid, namely linking at least one of the —COOH and the —OH comprised in the side chain of the repeating unit of the hyaluronic acid, directly or indirectly, to the following group: ##STR00087## R.sub.1 is selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; R.sub.2 and R.sub.3 are the same or different and independently from each other are selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; * represents a linking site; 2) reacting the acryloylated hyaluronic acid with a polysulfhydryl compound HS—R.sub.4—SH to obtain the sulfhydryl-modified hyaluronic acid, wherein R.sub.4 is defined as above.
7. The preparation method according to claim 6, characterized in that, the step 1) is the step of acryloylating the hyaluronic acid, namely linking at least one of the —COOH and the —OH comprised in the side chain of the repeating unit of the hyaluronic acid, directly or via an R group, to the terminal group to form the side chain of at least one of the following structures: ##STR00088## in the structures a, b, c and d, R, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above, and * represents a linking site.
8. The preparation method according to claim 7, characterized in that, in step 1), the acryloylating step can be performed by reacting a hyaluronic acid to be modified with an acrylate compound, or by reacting the hyaluronic acid to be modified with an acryloyl chloride compound or an acrylic anhydride compound.
9. The preparation method according to claim 6, characterized in that, in step 2), the reaction with the polysulfhydryl compound HS—R.sub.4—SH is performed in a solvent; preferably, in step 2), the reaction with the polysulfhydryl compound HS—R.sub.4—SH is performed under low to high temperature conditions; preferably, in step 2), the pH range for the reaction with the polysulfhydryl compound HS—R.sub.4—SH is −1 to 15.
10. Use of the sulfhydryl-modified hyaluronic acid according to claim 1, characterized in that the sulfhydryl-modified hyaluronic acid is used in the fields such as antioxidation health products, biopharmaceuticals, medical cosmetology and cosmetics and the like.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
DETAILED DESCRIPTION
[0095] [Sulfhydryl-Modified Hyaluronic Acid]
[0096] As described above, the present disclosure proves a series of sulfhydryl-modified hyaluronic acid compounds with a novel structure, wherein part or all of —COOH and/or —OH comprised in a side chain of a repeating unit of the hyaluronic acid are modified to form a side chain with the following terminal group:
##STR00003##
[0097] in the above group, * represents a linking site;
[0098] R.sub.1 is selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; specifically, the halogen, the aliphatic group and the aromatic group are further defined as below; preferably, R.sub.1 is selected from hydrogen, halogen, and an aliphatic group; more preferably, R.sub.1 is selected from hydrogen, halogen and C.sub.1-6 alkyl (e.g., methyl and ethyl);
[0099] R.sub.2 and R.sub.3 are the same or different and are independently selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; specifically, the halogen, the aliphatic group and the aromatic group are further defined as below;
[0100] R.sub.4 is a fragment of a polysulfhydryl compound.
[0101] In a specific embodiment, the terminal group is linked to the —COOH and/or the —OH through an R group or directly to the —COOH and/or the —OH to form a side chain of at least one of the following structures:
##STR00004##
[0102] in the structures a, b, c and d, R is selected from
##STR00005##
hydrocarbylene, arylene, an amide residue, a hydrazide residue, and the like; * represents a linking site; 1* represents a linking site to a left-hand group of R; 2* represents a linking site to a right-hand group of R; R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above.
[0103] The sulfhydryl-modified hyaluronic acid has a molecular weight ranging from 5 kDa to 20 MDa. The molecular weight of the sulfhydryl-modified hyaluronic acid changes little or remains substantially unchanged before and after modification.
[0104] A sulfhydryl content of the sulfhydryl-modified hyaluronic acid as determined by the Ellman method is 0.01-30 mmol/g, for example, 0.1-10.0 mmol/g, for another example, 0.3-5.0 mmol/g, and for yet another example, 0.5-3.0 mmol/g.
[0105] For example, the sulfhydryl-modified hyaluronic acid of the present disclosure comprises at least one of the following structures:
##STR00006##
[0106] wherein in the above structures, R, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above; (n2+n3)/(n1+n2+n3) represents a degree of acryloylation; n3/(n1+n2+n3) represents a degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method; the n1 can be 0, and if it is 0, the degree of acryloylation is not limited, and n3/(n2+n3) alone represents the degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method; the n2 can be 0, and if it is 0, n3/(n1+n3) represents both the degree of acryloylation and the degree of sulfhydrylation corresponding to the above sulfhydryl content of the sulfhydryl-modified polymer compound as determined by the Ellman method;
[0107] the A.sub.1 is:
##STR00007##
[0108] the A.sub.2 is one of the following structures:
##STR00008##
[0109] * in the structure of A.sub.1 and A.sub.2 represents a linking site to the COOH or the OH.
[0110] In the present disclosure, n1, n2, n3, n4, n5, n6, m1 and m2 are the number of repeating units in the structural formula unless otherwise specified. The range of values falls within conventional ranges known in the art.
[0111] As described above, R.sub.1 is selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like; R.sub.2 and R.sub.3 are the same or different and are independently selected from hydrogen, halogen, an aliphatic group, an aromatic group, and the like.
[0112] As described above, the R may be selected from hydrocarbylene, arylene, an amide residue, a hydrazide residue, and the like.
[0113] The halogen refers to fluorine, chlorine, bromine or iodine.
[0114] The aliphatic group is, for example, a straight-chain or branched saturated/unsaturated aliphatic group, specifically may be alkyl, alkenyl or alkynyl.
[0115] The “hydrocarbyl” used herein alone or as a suffix or prefix is, for example, a straight-chain or branched saturated/unsaturated aliphatic group, specifically may be alkyl, alkenyl or alkynyl.
[0116] The “alkyl” used herein alone or as a suffix or prefix is intended to include both branched and straight-chain saturated aliphatic hydrocarbyl groups having 1-20, preferably 1-6, carbon atoms. For example, “C.sub.1-6 alkyl” refers to a straight-chain or branched alkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.
[0117] The “alkenyl” used herein alone or as a suffix or prefix is intended to include both branched and straight-chain aliphatic hydrocarbyl groups comprising alkenyl or alkene having 2-20, preferably 2-6, carbon atoms (or the specific number of carbon atoms if provided). For example, “C.sub.2-6 alkenyl” refers to an alkenyl group having 2, 3, 4, 5 or 6 carbon atoms. Examples of alkenyl include, but are not limited to, ethenyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl, and 4-hexenyl.
[0118] The “alkynyl” used herein alone or as a suffix or prefix is intended to include both branched and straight-chain aliphatic hydrocarbyl groups comprising alkynyl or alkyne having 2-20, preferably 2-6 carbon atoms (or the specific number of carbon atoms if provided). For example, ethynyl, propynyl (e.g., 1-propynyl, 2-propynyl), 3-butynyl, pentynyl, hexynyl and 1-methylpent-2-ynyl.
[0119] The “hydrocarbylene” used herein is a group obtained by removing one hydrogen from the “hydrocarbyl”.
[0120] The aromatic group refers to an aromatic ring structure composed of 5-20 carbon atoms. For example, the aromatic ring structure containing 5, 6, 7 and 8 carbon atoms may be a monocyclic aromatic group, e.g., phenyl; the ring structure containing 8, 9, 10, 11, 12, 13 or 14 carbon atoms may be a polycyclic aromatic group, e.g., naphthyl. The aromatic ring may be substituted at one or more ring positions with substituents such as alkyl and halogen, e.g., tolyl. The term “aryl” also includes polycyclic ring systems having two or more rings in which two or more carbons are common to two adjacent rings (the rings are “fused rings”), and at least one of the rings is aromatic and the other rings may be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and/or heterocyclyl. Examples of polycyclic rings include, but are not limited to, 2,3-dihydro-1,4-benzodioxine and 2,3-dihydro-1-benzofuran.
[0121] The “arylene” used herein is a group obtained by removing one hydrogen from the “aromatic group”. The “amide group” used herein alone or as a suffix or prefix refers to the R.sup.a—C(═O)—NH— group, wherein R.sup.a is selected from the following groups unsubstituted or optionally substituted with one or more R.sup.b: alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, and the like; R.sup.b is selected from the following groups unsubstituted or optionally substituted with one or more R.sup.b1: halogen, hydroxyl, sulfhydryl, nitro, cyano, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, heterocyclyl, aryl, heteroaryl, amino, carboxyl, an ester group, hydrazino, acyl, sulfinyl, sulfonyl, phosphoryl, and the like; each R.sup.b1 is independently selected from halogen, hydroxy, alkyl and aryl.
[0122] The “hydrazide group” used herein alone or as a suffix or prefix refers to the R.sup.a—C(═O)—NH— group, wherein R.sup.a is defined as above.
[0123] The “amide residue” used herein is a group obtained by removing one hydrogen from the “amide group”.
[0124] The “hydrazide residue” used herein is a group obtained by removing one hydrogen from the “hydrazide group”.
[0125] The term “cycloalkyl” used herein is intended to include saturated cyclic groups having the specified number of carbon atoms. These terms may include fused or bridged polycyclic ring systems. The cycloalkyl has 3-40 carbon atoms in its ring structure. In one embodiment, the cycloalkyl has 3, 4, 5 or 6 carbon atoms in its ring structure. For example, “C.sub.3-6 cycloalkyl” refers to a group such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0126] The term “cycloalkenyl” used herein is intended to include cyclic groups comprising at least one alkenyl group having the specified number of carbon atoms. These terms may include fused or bridged polycyclic ring systems. The cycloalkenyl has 3-40 carbon atoms in its ring structure. In one embodiment, the cycloalkenyl has 3, 4, 5 or 6 carbon atoms in its ring structure. For example, “C.sub.3-6 cycloalkenyl” refers to a group such as cyclopropenyl, cyclobutenyl, cyclopentenyl or cyclohexenyl.
[0127] The term “cycloalkynyl” used herein is intended to include cyclic groups comprising at least one alkynyl group having the specified number of carbon atoms. These terms may include fused or bridged polycyclic ring systems. The cycloalkynyl has 6-40 carbon atoms in its ring structure. In one embodiment, the cycloalkynyl has 6 carbon atoms in its ring structure. For example, “C.sub.3-6 cycloalkynyl” refers to a group such as cyclopropynyl, cyclobutynyl, cyclopentynyl or cyclohexynyl. The “heteroaryl” used herein refers to a heteroaromatic heterocycle having at least one ring heteroatom (e.g., sulfur, oxygen, or nitrogen). The heteroaryl include monocyclic ring systems and polycyclic ring systems (e.g., having 2, 3 or 4 fused rings). Examples of heteroaryl include, but are not limited to, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuryl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, benzoxazolyl, azabenzoxazolyl, imidazothiazolyl, benzo[1,4]dioxanyl, benzo[1,3]dioxolyl, and the like. In some embodiments, the heteroaryl has 3-40 carbon atoms, and in other embodiments, 3-20 carbon atoms. In some embodiments, the heteroaryl contains 3-14, 4-14, 3-7, or 5-6 ring atoms. In some embodiments, the heteroaryl has 1-4, 1-3, or 1-2 heteroatoms. In some embodiments, the heteroaryl has 1 heteroatom.
[0128] The term “heterocyclyl” used herein refers to a saturated, unsaturated or partially saturated monocyclic, bicyclic or tricyclic ring containing 3-20 atoms, wherein 1, 2, 3, 4 or 5 ring atoms are selected from nitrogen, sulfur, oxygen or phosphorus, which, unless otherwise stated, may be linked through carbon or nitrogen, wherein the —CH.sub.2— group is optionally replaced by —C(O)—; wherein unless otherwise stated to the contrary, the ring nitrogen atom or the ring sulfur atom is optionally oxidized to form an N-oxide or S-oxide, or the ring nitrogen atom is optionally quaternized; wherein —NH in the ring is optionally substituted with acetyl, formyl, methyl, or methanesulfonyl; and the ring is optionally substituted with one or more halogens. It should be understood that when the total number of S and O atoms in the heterocyclic group exceeds 1, these heteroatoms are not adjacent to each other. If the heterocyclyl is a bicyclic or tricyclic ring, at least one ring may optionally be a heteroaromatic or aromatic ring, provided that at least one ring is non-heteroaromatic. If the heterocyclyl is a monocyclic ring, it cannot be aromatic. Examples of heterocyclyl include, but are not limited to, piperidyl, N-acetylpiperidyl, N-methylpiperidyl, N-formylpiperazinyl, N-methanesulfonylpiperazinyl, homopiperazinyl, piperazinyl, azetidinyl, oxetanyl, morpholinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, indolinyl, tetrahydropyranyl, dihydro-2H-pyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl, tetrahydrothiopyran-1-oxide, tetrahydrothiopyran-1,1-dioxide, 1H-pyridin-2-one, and 2,5-dioxoimidazolidinyl.
[0129] The term “acyl” used herein refers to the R.sup.a—C(═O)— group, wherein R.sup.a is defined as above.
[0130] The term “sulfinyl” used herein refers to the R.sup.a—S(═O)— group, wherein R.sup.a is defined as above.
[0131] The term “sulfonyl” used herein refers to the R.sup.a—S(═O).sub.2— group, wherein R.sup.a is defined as above.
[0132] The term “phosphoryl” used herein refers to the R.sup.c—P(═O)(R.sup.d)— group, wherein R.sup.c and R.sup.d are the same or different and are independently selected from the following groups, unsubstituted or optionally substituted with one or more R.sup.b: alkyl, cycloalkyl, alkoxy, hydroxyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, and the like; R.sup.b is defined as above.
[0133] The term “hydrazino” used herein refers to the —NHNHR.sup.a group, wherein R.sup.a is defined as above.
[0134] The term “amine group” used herein refers to the —NHR.sup.a group or the —N(R.sup.a).sub.2 group, wherein R.sup.a is defined as above.
[0135] The term “amino” used herein refers to the —NH.sub.2 group.
[0136] The term “carboxyl” used herein refers to the —COOH group.
[0137] The term “ester group” used herein refers to the R.sup.a—C(═O)—O— group or the R.sup.a—O—C(═O)— group, wherein R.sup.a is defined as above.
[0138] As described above, R.sub.4 is a fragment of the polysulfhydryl compound, that is, an —S—R.sub.4—SH fragment can be introduced from the polysulfhydryl compounds including but not limited to:
##STR00009##
[0139] wherein n4 is an integer from 2 to 30, such as 2, 3, 4, 5 or 6; n5 is an integer from 1 to 30, such as 1, 2, 3, 4 or 5; n6 is an integer from 1 to 30, such as 1, 2, 3, 4 or 5;
[0140] 4-arm-PEG-SH represents a PEG polymer containing four sulfhydryl groups; 6-arm-PEG-SH represents a PEG polymer containing six sulfhydryl groups; 8-arm-PEG-SH represents a PEG polymer containing eight sulfhydryl groups; the PEG is an abbreviation for polyethylene glycol.
[0141] Specifically, the sulfhydryl-modified hyaluronic acid has at least one of the structures including but not limited to:
##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025## ##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
in the above structural formulas, n.sup.1, n.sub.2 and n.sub.3 are defined as above.
[0142] For the sulfhydryl-modified hyaluronic acid of the present disclosure, there are three indexes and determination methods commonly used to characterize the physicochemical properties: intrinsic viscosity determination, in which the intrinsic viscosity is an effective parameter for characterizing the molecular weight of a polymer compound, corresponding to high performance gel permeation chromatography and multi-angle laser light scattering combined with gel permeation chromatography; water retention rate determination; and oxidation resistance determination. As described above, the viscosity, water retention, and oxidation resistance are the main physicochemical properties of the hyaluronic acid, which are closely related to the application range of the hyaluronic acid. Specifically, in the characterization of physicochemical properties of the series of sulfhydryl-modified hyaluronic acid compounds described herein, the viscosity is the most important performance index, which is not only an external index of molecular weight, but also a key index that affects the therapeutic or plastic effect of each sulfhydryl-modified hyaluronic acid in human body. Large viscosity makes the sulfhydryl-modified hyaluronic acid more difficult to disperse in tissues, thereby reducing the absorption rate of such compounds by tissues, and keeping them in human body for a longer period of time, i.e., increasing their metabolic half-life in vivo. In addition, the water retention and moisture supplement function is an important functional index of such compounds used in clinic, cosmetics and the like, and the water retention rate is an important index for evaluating such compounds and a comparative index for superiority. The oxidation resistance is also a main functional index of the sulfhydryl-modified hyaluronic acid involved in the present disclosure, and is also a main functional index of such compounds used in antioxidation cosmetics, antioxidation health care products and antioxidation medical products. There have been perfect testing methods and evaluation systems for determining the oxidation resistance.
[0143] The intrinsic viscosity determination is a method for calculating the molecular weight of a polymer by utilizing the rheological property thereof, which is simple and easy to implement, and is widely used today. For example, the sodium hyaluronate examination item recorded in European pharmacopoeia and British pharmacopoeia is used to control the quality and hence the molecular weight of the sodium hyaluronate by the intrinsic viscosity determination. This determination does not need reference substances, but it is greatly affected by the purity of the sample, and the content of hyaluronic acid in the solution needs to be accurately determined. The intrinsic viscosity determination is the most commonly used method for determining the molecular weight of hyaluronic acid because it does not require expensive equipments, and has simple operation and accurate results. At present, when determining the molecular weight of hyaluronic acid solution by this determination, the solution is first precipitated with ethanol, and the precipitate is collected and dried to obtain a solid before determination. However, this determination has poor accuracy in terms of the complex results, and is time consuming. The intrinsic viscosity determination is close to the method for directly determining the viscosity of such polymer compounds that is also an important characteristic physicochemical index related to the molecular weight of such polymer compounds. In addition, the other two methods for characterizing the molecular weight of such polymer compounds are high performance gel permeation chromatography and multi-angle laser light scattering combined with gel permeation chromatography.
[0144] High performance gel permeation chromatography (HPGPC) is a liquid chromatography technique for separating molecules according to their size, with the retention time of a material passing through a column being linearly and negatively correlated with the logarithm of its molecular weight. The method has good reproducibility and high speed, and can measure the average molecular weight and the distribution thereof. However, the determination of molecular weight by HPGPC requires the correction of the corresponding reference substance, and the hyaluronic acid reference substance is generally difficult to obtain, so that only samples with similar structures can be selected as the reference substance. Due to the different structure from the hyaluronic acid, the reference substance has different molecular weight, which causes the determined molecular weights of the sample to deviate from the true value.
[0145] Multi-angle laser light scattering combined with gel permeation chromatography (GPC/MALLS) can obtain the concentration and molecular weight of each fraction point in the sample elution profile for polymer samples in any molecular weight range regardless of the molecular state in the mobile phase. This method can obtain the molecular weight of the sample without a reference substance, and the determination result is accurate and reliable. However, the instrument is expensive, and in ultra-high molecular weight measurements, the sample may undergo shear degradation in the porous medium or block the gel column. Therefore, the application of this method is limited.
[0146] The water retention rate determination comprises the following steps: on the basis of selecting a proper sample and an effect comparison sample, the water retention property of different biocompatible high polymer materials is determined, mainly including indexes such as water absorption multiple in pure water, liquid absorption multiple in proper solutions, water absorption rate in pure water or proper solutions, water retention, repeated water absorption, liquid absorption property of the simulated liquid for use in the a human body environment and the like, wherein the simulated liquid for use in the a human body environment includes the simulated tissue fluid, the simulated cell fluid and the like. All tests must be repeated and validated.
[0147] The water absorption multiples (Q) of different water-retaining agents are determined according to the following formula: (m2−m1)/m1, where m1 and m2 represents the mass of the water-retaining agent for the biocompatible polymer compound in a dry state of the mass standard and in a saturated state by water absorption, which is usually expressed in grams. The dry state of the mass standard means that the water content of the finished product does not exceed 10%.
[0148] The water absorption rates of different biocompatible polymer compounds are determined according to the filtration method for determining the water absorption rate. Several parts of about 1 g or proper weights of biocompatible polymer are taken, precisely weighed, placed in water or different solutions and left to stand, and then filtered and weighed at different time points in sequence to obtain the water absorption rate of the water-retaining agent at different time points.
[0149] The oxidation resistance determination: the oxidation resistance determination of biocompatible polymer materials related to the present patent: the oxidation resistance of each biocompatible polymer compound is evaluated by the capacity of removing free radicals, wherein the removing free radicals mainly refers to removing oxygen free radicals, which has a mature and well-known determination method in the pharmaceutical industry.
[Preparation Method for Sulfhydryl-modified Hyaluronic Acid]
[0150] As described above, the present disclosure provides a preparation method for the sulfhydryl-modified hyaluronic acid, which comprises the following steps:
[0151] 1) acryloylating the hyaluronic acid, namely linking at least one of the —COOH and the —OH comprised in the side chain of the repeating unit of the hyaluronic acid, directly or indirectly, to the following group:
##STR00042##
[0152] wherein R.sub.1, R.sub.2 and R.sub.3 are defined as above, and * represents a linking site;
[0153] 2) reacting the acryloylated hyaluronic acid with a polysulfhydryl compound HS—R.sub.4—SH to obtain the sulfhydryl-modified hyaluronic acid, wherein R.sub.4 is defined as above.
[0154] Specifically, the step 1) is as follows: acryloylating the hyaluronic acid, namely linking at least one of the —COOH and the —OH comprised in the side chain of the repeating unit of the hyaluronic acid, via an R group or directly, to the terminal group to form the side chain of at least one of the following structures:
##STR00043##
[0155] in the structures a, b, c and d, R, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as above, and * represents a linking site.
[0156] In step 1), the acryloylating step can be performed by reacting a hyaluronic acid to be modified with an acrylate compound, or by reacting the hyaluronic acid to be modified with an acryloyl chloride compound or an acrylic anhydride compound.
[0157] The acrylate compound may be one or more of an alkyl acrylate compound, an aryl acrylate compound and a glycidyl acrylate polyol compound.
[0158] The polyol in the glycidyl acrylate polyol compound is, for example, a triol, specifically, glycerin, butanetriol, pentanetriol, and the like.
[0159] In step 1), the acryloylating step may be a conventional reaction step, which can be performed under existing conventional conditions. Generally, it is performed by reacting acryloyl chloride and derivatives thereof or acrylic anhydride and derivatives thereof with the hyaluronic acid to be modified. It is also performed by reacting glycidyl acrylate and derivatives thereof with the hyaluronic acid to be modified.
[0160] In step 1), the acryloylating step can be an unconventional reaction step, namely using a method other than the above method to synthesize a polymer compound comprising at least one of the structures a, b, c and d.
[0161] In step 1), the structure of the product obtained from the acryloylating step is at least one of the following structures:
##STR00044##
[0162] in the above structures, R, R.sub.1, R.sub.2 and R.sub.3 are defined as above, and (m2)/(m1+m2) represents the degree of acryloylation.
[0163] In step 2), the reaction with the polysulfhydryl compound HS—R.sub.4—SH is performed in a solvent. The solvent is, for example, water or an organic solvent, and further can be deionized water or dimethylformamide.
[0164] In step 2), the reaction with the polysulfhydryl compound HS—R.sub.4—SH is performed under low to high temperature conditions. For example, the reaction temperature is 0-80° C., and further can be 10-70° C., and for example, the reaction can be performed at room temperature.
[0165] In step 2), the reaction time for the reaction with the polysulfhydryl compound HS—R.sub.4—SH is 0.1-100 h.
[0166] In step 2), the pH range for the reaction with the polysulfhydryl compound HS—R.sub.4—SH is −1 to 15. For example, the reaction pH can be 6-8, and for another example, 7.
[0167] In step 2), the reaction further comprises a post-treatment step.
[0168] In the post-treatment step, a dialysis method is adopted. Specifically, the solution after the reaction is filled into a dialysis bag (for example, a dialysis bag with a molecular weight cutoff of 2 kDa or more), dialyzed against a hydrochloric acid solution (for example, at pH 4) for several days (for example, 1-10 days, for another example, 5 days, and the like), optionally refreshed with water (for example, refreshed with water every day or every other day) for several times (for example, twice or more, and the like), and finally collected and dried (for example, lyophilized) to obtain a solid, i.e., the sulfhydryl-modified hyaluronic acid derivative.
[0169] The present disclosure firstly provides a preparation method for the sulfhydryl-modified hyaluronic acid by the Michael addition reaction of the sulfhydryl of the polysulfhydryl compound with the carbon-carbon double bond in the acryloyl group. The method has a high degree of sulfhydrylation, mild conditions for the sulfhydrylation reaction (can be performed at room temperature in an aqueous solution) and no pollution, and the prepared sulfhydryl-modified hyaluronic acid has high purity and is particularly suitable for further use in the fields such as pharmaceuticals, cosmetology and medicine.
[0170] [Application of Sulfhydryl-Modified Hyaluronic Acid]
[0171] As described above, the present disclosure also provides use of the sulfhydryl-modified hyaluronic acid for the fields such as antioxidation health care products, biopharmaceuticals, medical cosmetology and cosmetics (e.g., at least one of antioxidation cosmetics and water retention and moisture supplement cosmetics).
[0172] It is known that hyaluronic acid (HA) is a linear, non-branched macromolecular acidic mucopolysaccharide polymer composed of repeated and alternating linkages of disaccharides (the structural units are β-(1,4)-N-acetyl-D-glucosamine and β-(1,3)-D-glucuronic acid). The chain length of HA varies from about 5 kDa to 20 MDa, with the range from 2 MDa to 5 MDa being the most common. More than 50% of hyaluronic acid is present in skin, lung and intestinal tissue. In addition, it is also present in interstitial tissues such as synovial fluid, cartilage, umbilical cord, and vascular wall. Hyaluronic acid in the human body mainly exerts physiological functions such as lubrication and buffering, filling and diffusion barrier, and free radical removal. Currently marketed hyaluronic acid products can be extracted from animal tissues (such as cockscomb, lens of eye, cerebral cartilage and synovial fluid), or prepared by the fermentation of bacteria (such as streptococcus and Pseudomonas aeruginosa). In recent years, with the in-depth research on the functions of HA, HA has been widely used in the pharmaceutical field, such as for the preparation of drug delivery systems, for the treatment of orthopedic and ophthalmic diseases, and for the prevention of post-operative adhesions and the repairing of soft tissues, which has become a research hot spot in the fields of tissue engineering and regenerative medicine. Although natural HA has excellent biocompatibility and anti-inflammatory effects, it has poor mechanical strength and degradability when in a pure state. Therefore, as a scaffold material for tissue engineering, HA must be chemically modified in a suitable way or used in combination with other materials to improve those deficiencies, to better exert its biological effects, and to provide a good environment for the survival and function of cells and the repairing and regeneration of tissues.
[0173] In the present disclosure, the sulfhydryl-modified hyaluronic acid is prepared and recorded as HA-SH, which can be cross-linked by thiol oxidation to form a stable cross-linked material (e.g., hydrogel) with excellent mechanical properties, good physical stability and mechanical strength; in addition, the in vivo metabolic rate is controllable, and the HA-SH can also be used with other components of biological functional materials make up for each other's deficiencies, thus obtaining a three-dimensional scaffold material with excellent properties that can meet the requirements of most tissue engineering applications.
[0174] The present disclosure will be further illustrated with reference to the following specific examples. It should be understood that these examples are merely intended to illustrate the present disclosure rather than limit the protection scope of the present disclosure. In addition, it should be understood that various changes or modifications may be made by those skilled in the art after reading the teachings of present disclosure, and these equivalents also fall within the protection scope of the present disclosure.
[0175] In the present disclosure, the .sup.1H-NMR spectrum is determined by a Varian 400 MHz nuclear magnetic resonance spectrometer, with the test temperature of 25° C., the relaxation time of 1 s, and the number of scanning of 8. Specifically, 8-10 mg of the test sample is dissolved in 750 μL of deuterated water, and the obtained sample solution is determined for the .sup.1H-NMR spectrum.
Preparation Example 1. Synthesis of Acrylate-Modified Hyaluronic Acid (HA-A1)
[0176] To a 200 mL beaker were added 1 g of hyaluronic acid (Bloomage Freda, weight-average molecular weight: about 300 kDa), 50 mL of deionized water, 50 mL of dimethylformamide, 12 mL of triethylamine, and 14 mL of glycidyl acrylate. After being stirred at room temperature until uniform and transparent, the mixture was stirred for an additional 48 h. 300 mL of acetone was added, and a large amount of white precipitate was generated. The reaction solution was centrifuged, and the resulting precipitate was dissolved in 100 mL of deionized water to obtain a colorless transparent solution. The resulting solution was filled into a dialysis bag (molecular weight cutoff: 8 kDa) and dialyzed against 5 L of deionized water for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A1 (921 mg, yield 92.1%) as a white flocculent solid.
[0177] The structural formula of HA-A1 is shown in
[0178] The .sup.1H-NMR spectrum of HA-A1 is shown in
Preparation Example 2. Synthesis of Acrylate-Modified Hyaluronic Acid (HA-A2)
[0179] To a 200 mL beaker were added 1 g of hyaluronic acid (Bloomage Freda, weight-average molecular weight: about 400 kDa), 50 mL of deionized water, 50 mL of dimethylformamide, and 6.3 g of acrylic anhydride, and the mixture was dissolved with stirring. The solution was maintained at pH 8±0.5 with 1 mol/L NaOH, and stirred for an additional 24 h. 300 mL of acetone was added, and a large amount of white precipitate was generated. The reaction solution was centrifuged, and the resulting precipitate was dissolved in 100 mL of deionized water to obtain a colorless transparent solution. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of deionized water for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2 (789 mg, yield 78.9%) as a white flocculent solid.
[0180] The structural formula of HA-A2 is shown in
[0181] The .sup.1H-NMR spectrum of HA-A2 is shown in
Preparation Example 3. Synthesis of Methacrylate-Modified Hyaluronic Acid (HA-MA1)
[0182] To a 200 mL beaker were added 1 g of hyaluronic acid (Bloomage Freda, weight-average molecular weight: about 400 kDa), 50 mL of deionized water, 50 mL of dimethylformamide (Sigma), 12 mL of triethylamine (Sigma), and 15 mL of glycidyl methacrylate. After being stirred at room temperature until uniform and transparent, the mixture was stirred for an additional 48 h. 300 mL of acetone (Sigma) was added, and a large amount of white precipitate was generated. The reaction solution was centrifuged, and the resulting precipitate was dissolved in 100 mL of deionized water to obtain a colorless solution. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of deionized water for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA1 (859 mg, yield 85.9%) as a white flocculent solid.
[0183] The structural formula of HA-MA1 is shown in
[0184] The .sup.1H-NMR spectrum of HA-MA1 is shown in
Preparation Example 4. Synthesis of Methacrylate-Modified Hyaluronic Acid (HA-MA2)
[0185] To a 200 mL beaker were added 1 g of hyaluronic acid (Bloomage Freda, weight-average molecular weight: about 400 kDa) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature. Further, 7.7 g of methacrylic anhydride was added and dissolved with stirring. The solution was maintained at pH 8±0.5 with 1 mol/L NaOH, and stirred for an additional 24 h. 200 mL of acetone (Sigma) was added, and a large amount of white precipitate was generated. The reaction solution was centrifuged, and the resulting precipitate was dissolved in 100 mL of deionized water to obtain a colorless transparent solution. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of deionized water for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA2 (846 mg, yield 84.6%) as a white flocculent solid.
[0186] The structural formula of HA-MA2 is shown in
[0187] The .sup.1H-NMR spectrum of HA-MA2 is shown in
Example 1. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A1-SH1)
[0188] To a 200 mL beaker were added 1 g of HA-A1 prepared according to the method of Preparation Example 1, 0.3 g of dithiothreitol (VWR) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A1-SH1 (842 mg, yield 84.2%) as a white flocculent solid.
[0189] The reaction equation for HA-A1-SH1 is shown in
[0190] The .sup.1H-NMR spectrum of HA-A1-SH1 is shown in
Example 2. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH1)
[0191] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.3 g of dithiothreitol (VWR) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH1 (827 mg, yield 82.7%) as a white flocculent solid.
[0192] The reaction equation for HA-A2-SH1 is shown in
[0193] The .sup.1H-NMR spectrum of HA-A2-SH1 is shown in
Example 3. Synthesis of Sulfhydryl-Methacrylate-Modified Hyaluronic Acid (HA-MA1-SH1)
[0194] To a 200 mL beaker were added 1 g of HA-MA1 prepared according to the method of Preparation Example 3, 0.3 g of dithiothreitol (VWR) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA1-SH1 (854 mg, yield 85.4%) as a white flocculent solid.
[0195] The reaction equation for HA-MA1-SH1 is shown in
[0196] The .sup.1H-NMR spectrum of HA-MA1-SH1 is shown in
Example 4. Synthesis of Sulfhydryl-Methacrylate-Modified Hyaluronic Acid (HA-MA2-SH1)
[0197] To a 200 mL beaker were added 1 g of HA-MA2 prepared according to the method of Preparation Example 4, 0.3 g of dithiothreitol (VWR) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA2-SH1 (833 mg, yield 83.3%) as a white flocculent solid.
[0198] The reaction equation for HA-MA2-SH1 is shown in
[0199] The .sup.1H-NMR spectrum of HA-MA2-SH1 is shown in
Example 5. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A1-SH2)
[0200] To a 200 mL beaker were added 1 g of HA-A1 prepared according to the method of Preparation Example 1, 0.42 g of 1,4-butanedithiol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A1-SH2 (852 mg, yield 85.2%) as a white flocculent solid.
[0201] The reaction equation for HA-A1-SH2 is shown in
[0202] The .sup.1H-NMR spectrum of HA-A1-SH2 is shown in
Example 6. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A1-SH3)
[0203] To a 200 mL beaker were added 1 g of HA-A1 prepared according to the method of Preparation Example 1, 0.43 g of 2-amino-1,4-butanedithiol hydrochloride (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A1-SH3 (843 mg, yield 84.3%) as a white flocculent solid.
[0204] The reaction equation for HA-A1-SH3 is shown in
[0205] The .sup.1H-NMR spectrum of HA-A1-SH3 is shown in
Example 7. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH2)
[0206] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.42 g of 1,4-butanedithiol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH2 (827 mg, yield 82.7%) as a white flocculent solid.
[0207] The reaction equation for HA-A2-SH2 is shown in
[0208] The .sup.1H-NMR spectrum of HA-A2-SH2 is shown in
Example 8. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH3)
[0209] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.43 g of 2-amino-1,4-butanedithiol hydrochloride (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH3 (833 mg, yield 83.3%) as a white flocculent solid.
[0210] The reaction equation for HA-A2-SH3 is shown in
[0211] The .sup.1H-NMR spectrum of HA-A2-SH3 is shown in
Example 9. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH4)
[0212] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.38 g of 1,3-propanedithiol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH4 (814 mg, yield 81.4%) as a white flocculent solid.
[0213] The reaction equation for HA-A2-SH4 is shown in
[0214] The .sup.1H-NMR spectrum of HA-A2-SH4 is shown in
Example 10. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH5)
[0215] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.52 g of 1,3-phenyldithiophenol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH5 (836 mg, yield 83.6%) as a white flocculent solid.
[0216] The reaction equation for HA-A2-SH5 is shown in
[0217] The .sup.1H-NMR spectrum of HA-A2-SH5 is shown in
Example 11. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH6)
[0218] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.52 g of 1,4-phenyldithiophenol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH6 (831 mg, yield 83.1%) as a white flocculent solid.
[0219] The reaction equation for HA-A2-SH6 is shown in
[0220] The .sup.1H-NMR spectrum of HA-A2-SH6 is shown in
Example 12. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH7)
[0221] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.96 g of sulfhydryl polyethylene glycol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH7 (894 mg, yield 89.4%) as a white flocculent solid.
[0222] The reaction equation for HA-A2-SH7 is shown in
[0223] The .sup.1H-NMR spectrum of HA-A2-SH7 is shown in
Example 13. Synthesis of Sulfhydryl-Acrylate-Modified Hyaluronic Acid (HA-A2-SH8)
[0224] To a 200 mL beaker were added 1 g of HA-A2 prepared according to the method of Preparation Example 2, 0.74 g of trimethylolpropane-tris(3-sulfhydrylpropionate) (Sigma), 50 mL of deionized water and 50 mL of dimethylformamide, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-A2-SH8 (785 mg, yield 78.5%) as a white flocculent solid.
[0225] The reaction equation for HA-A2-SH8 is shown in
[0226] The .sup.1H-NMR spectrum of HA-A2-SH8 is shown in
Example 14. Synthesis of Sulfhydryl-Methacrylate-Modified Hyaluronic Acid (HA-MA1-SH5)
[0227] To a 200 mL beaker were added 1 g of HA-MA1 prepared according to the method of Preparation Example 3, 0.50 g of 1,3-phenyldithiophenol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA1-SH5 (828 mg, yield 82.8%) as a white flocculent solid.
[0228] The reaction equation for HA-MA1-SH5 is shown in
[0229] The .sup.1H-NMR spectrum of HA-MA1-SH5 is shown in
Example 15. Synthesis of Sulfhydryl-Methacrylate-Modified Hyaluronic Acid (HA-MA1-SH6)
[0230] To a 200 mL beaker were added 1 g of HA-MA1 prepared according to the method of Preparation Example 3, 0.50 g of 1,4-phenyldithiophenol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA1-SH6 (833 mg, yield 83.3%) as a white flocculent solid.
[0231] The reaction equation for HA-MA1-SH6 is shown in
[0232] The .sup.1H-NMR spectrum of HA-MA1-SH6 is shown in
Example 16. Synthesis of Sulfhydryl-Methacrylate-Modified Hyaluronic Acid (HA-MA2-SH7)
[0233] To a 200 mL beaker were added 1 g of HA-MA2 prepared according to the method of Preparation Example 4, 0.92 g of sulfhydryl polyethylene glycol (Sigma) and 100 mL of deionized water, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA2-SH7 (876 mg, yield 87.6%) as a white flocculent solid.
[0234] The reaction equation for HA-MA2-SH7 is shown in
[0235] The .sup.1H-NMR spectrum of HA-MA2-SH7 is shown in
Example 17. Synthesis of Sulfhydryl-Methacrylate 2-Modified Hyaluronic Acid (HA-MA2-SH8)
[0236] To a 200 mL beaker were added 1 g of HA-MA2 prepared according to the method of Preparation Example 4, 0.68 g of trimethylolpropane-tris(3-sulfhydrylpropionate) (Sigma), 50 mL of deionized water and 50 mL of dimethylformamide, and the mixture was dissolved with stirring at room temperature to obtain a transparent solution. The resulting transparent solution was stirred for an additional 12 h. The resulting solution was filled into a dialysis bag (Spectrumlabs, molecular weight cutoff: 8 kDa) and dialyzed against 5 L of hydrochloric acid solution at pH 4 for 5 days, with water refreshed twice a day. Finally, the solution in the dialysis bag was collected and lyophilized to obtain HA-MA2-SH8 (825 mg, yield 82.5%) as a white flocculent solid.
[0237] The reaction equation for HA-MA2-SH8 is shown in
[0238] The .sup.1H-NMR spectrum of HA-MA2-SH8 is shown in
Example 18. Determination of Sulfhydryl Content of Sulfhydryl-Modified Polymer Compounds by Ellman Method
[0239] Preparation Process:
[0240] 1. Preparation of a test buffer: 0.1 mol/L Na.sub.2HPO.sub.4 (containing 1 mmol/L EDTA, adjusted to pH 8.0 with concentrated hydrochloric acid).
[0241] 2. Preparation of a standard working solution: 30 mmol/L cysteine solution.
[0242] 3. Preparation of an Ellman reagent stock solution: 0.1 mol/L Ellman reagent solution.
[0243] 4. Preparation of a standard solution:
TABLE-US-00001 Molar concentration 0 0.5 1.0 1.5 2.0 of sulfhydryl mmol/L mmol/L mmol/L mmol/L mmol/L Standard working 0 4 8 12 16 solution (μL) Buffer (μL) 240 236 232 228 224 Total volume (μL) 240 240 240 240 240
[0244] 5. Preparation of a test sample solution: an appropriate amount of the sulfhydryl-modified polymer compound sample was dissolved in the buffer to prepare 1 mg/mL solution to be tested (triplicates for each sample).
[0245] Testing Process:
[0246] 1. The cysteine standard solution was prepared in a 0.5 mL centrifuge tube according to step 4 above.
[0247] 2. In an additional 1.5 mL centrifuge tube, 50 μL of Ellman assay solution was added to 1 mL buffer to obtain an assay solution.
[0248] 3. 240 μL of the standard solution/test sample solution were each mixed with the Ellman assay solution in step 2 of the testing process, and reacted at room temperature for 15 min.
[0249] 4. After 15 min, the absorbance at 412 nm was determined using a microplate reader.
[0250] 5. The thiol content in the product can be calculated according to the absorbance/concentration standard curve of the obtained standard solution.
[0251] The standard curve of the sulfhydryl content is shown in
Example 19. Determination of Dynamic Viscosity of Sulfhydryl-Modified HA
[0252] 500 mg of sulfhydryl-modified polymer compound was dissolved in 50 mL of deionized water to obtain a 1% w/v solution. The dynamic viscosity of the resulting solution was determined at 25° C. using a rotary viscometer. The results are shown in Table 1.
TABLE-US-00002 TABLE 1 Determination results of sulfhydryl content and dynamic viscosity of sulfhydryl-modified polymer compounds Ellman Determination assay results of results viscosity Sulfhydryl Dynamic content viscosity Sample (mmol/g) (mPa .Math. s) HA-A1-SH1 1.357 420 HA-A2-SH1 1.424 416 HA-MA1-SH1 1.322 387 HA-MA2-SH1 1.362 441 HA-A1-SH2 1.428 452 HA-A1-SH3 1.347 398 HA-A2-SH2 1.471 435 HA-A2-SH3 1.413 412 HA-A2-SH4 1.458 487 HA-A2-SH5 1.347 437 HA-A2-SH6 1.298 416 HA-A2-SH7 0.974 473 HA-A2-SH8 2.471 451 HA-MA1-SH5 1.242 436 HA-MA1-SH6 1.317 429 HA-MA2-SH7 0.857 481 HA-MA2-SH8 2.146 447
Example 20. Determination of Molecular Weight and Distribution of Sulfhydryl-Modified Polymer Compounds by GPC
[0253] The mobile phase of GPC was 0.05 M sodium sulfate solution, with a flow rate of 1 mL/min and a column temperature of 30° C. The curve of the standard polyethylene glycol polymer was used as the standard curve.
[0254] 5 mg of sulfhydryl-modified HA was dissolved in 1 mL of 0.05 M sodium sulfate solution, filtered through a 0.22 μM filter, and determined by GPC. The results of molecular weight and distribution are shown in Table 2.
TABLE-US-00003 TABLE 2 Determination results of the molecular weight and molecular weight distribution of sulfhydryl-modified HA Sample Mn (Da) Mw (Da) PDI HA-A1-SH1 114599 338178 2.95 HA-A2-SH1 90222 426199 4.72 HA-MA1-SH1 74053 454233 6.13 HA-MA2-SH1 52132 427591 8.20 HA-A1-SH2 102221 454335 4.44 HA-A1-SH3 72720 429952 5.91 HA-A2-SH2 103770 373400 3.60 HA-A2-SH3 83819 411866 4.91 HA-A2-SH4 73382 417944 5.70 HA-A2-SH5 57322 416987 7.27 HA-A2-SH6 76601 337406 4.40 HA-A2-SH7 77628 419439 5.40 HA-A2-SH8 61804 375555 6.08 HA-MA1-SH5 63887 391562 6.13 HA-MA1-SH6 108308 397962 3.67 HA-MA2-SH7 69148 373393 5.40 HA-MA2-SH8 99257 337377 3.39
Example 21. Determination of Water Retention of Sulfhydryl-Modified HA
[0255] 50 mg of sulfhydryl-modified HA was added to a 20 mL glass bottle weighed in advance, and dissolved with 5 mL of deionized water to obtain a 1% solution. The mass of the solution m.sub.0 was obtained by the mass subtraction method. The glass bottle was placed in a shaker at 37° C., and weighed at regular intervals to obtain the mass of the solution m.sub.t. The water retention of the sulfhydryl-modified HA can be calculated according to the following formula:
Water retention percentage (%)=m.sub.t/m.sub.0×100%.
[0256] The results of water retention rate are shown in Table 3.
TABLE-US-00004 TABLE 3 Comparison table of water retention rate index Water retention rate Time point (day) Sample 0 1 2 4 6 HA-A1-SH1 100% 92.7% 81.1% 50.3% 25.9% HA-A2-SH1 100% 93.4% 81.7% 49.1% 27.6% HA-MA1-SH1 100% 91.6% 79.1% 46.9% 25.4% HA-MA2-SH1 100% 92.6% 82.3% 48.5% 28.1% HA-A1-SH2 100% 89.4% 76.1% 39.5% 16.9% HA-A1-SH3 100% 89.2% 77.6% 41.6% 18.5% HA-A2-SH2 100% 88.6% 74.4% 36.7% 15.6% HA-A2-SH3 100% 86.9% 77.8% 33.2% 13.9% HA-A2-SH4 100% 91.5% 81.5% 38.3% 21.4% HA-A2-SH5 100% 89.4% 80.5% 38.8% 21.1% HA-A2-SH6 100% 87.8% 76.8% 47.5% 24.5% HA-A2-SH7 100% 88.5% 77.4% 46.5% 26.2% HA-A2-SH8 100% 86.8% 74.9% 44.4% 24.8% HA-MA1-SH5 100% 87.7% 78.3% 46.5% 26.6% HA-MA1-SH6 100% 84.7% 72.1% 37.4% 16.0% HA-MA2-SH7 100% 84.3% 73.5% 39.4% 18.4% HA-MA2-SH8 100% 83.9% 70.5% 34.8% 14.8%
Example 22. Determination of Oxidation Resistance of Sulfhydryl-Modified HA by DPPH Free Radical Capture Method
[0257] An absolute ethanol solution of 25 μmol/L 1,1-diphenyl-2-trinitrophenylhydrazine (TNBS) was precisely prepared as a working solution. A certain amount of working solution was diluted with ethanol to obtain a series of standard solutions (0 μmol/L, 5 μmol/L, 10 μmol/L, 15 μmol/L, 20 μmol/L and 25 μmol/L).
[0258] The PBS solutions of sulfhydryl-modified HA were precisely prepared to obtain a series of test sample solutions at 0.1 mg/mL.
[0259] 90 μL of TNBS working solution and 10 μL of test sample solution were mixed well, and stored away from light at room temperature for 30 min. After that, the absorbance of the TNBS standard solution and the test sample mixed solution was determined at 517 nm for plotting a standard curve, and the concentration of the residual DPPH in the test sample was calculated according to the obtained standard curve. The free radical capture capacity (%) of the test sample was calculated according to the following formula:
Free radical capture capacity (%)=(1−(C.sub.sample/C.sub.DPPH))×100%.
[0260] The DPPH standard curve is shown in
[0261] The free radical capture capacity is shown in
Example 23. Superior Example of Cellular Activity of HA-SH of the Present Disclosure
[0262] The cellular activity and biocompatibility of HA-SH of the present disclosure were tested with reference to the criteria set forth in “GBT 16886.5-2017 Biological evaluation of medical devices—Part 5. Tests for in vitro cytotoxicity”. Specifically, the following MTT method, also known as MTT colorimetric method, is a method used to detect the survival and growth of cells. The detection principle is that succinate dehydrogenase in mitochondria of living cells can reduce exogenous MTT into water-insoluble purple crystalline Formazan and deposit the Formazan in the cells, while dead cells do not have this function. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and its absorbance at 490 nm can be determined by using an enzyme linked immunosorbent assay detector, so that the number of living cells can be indirectly reflected. Within a certain range of cell number, MTT crystals are formed in an amount proportional to the cell number. The specific test procedures and results are as follows:
[0263] The sulfhydryl-acrylate-modified hyaluronic acids prepared in Examples 1˜4 were prepared as 10 mg/mL PBS solutions with the pH adjusted to 7.35-7.45.
[0264] The test samples of the present disclosure were diluted to the following concentrations using cell culture prepared with Dulbecco's Modified Eagle Medium, 10% fetal bovine serum and 1% penicillin/streptomycin solution: 100 μg/mL, 500 μg/mL, 1000 μg/mL, 2500 μg/mL, 5000 μg/mL and 10000 μg/mL. The blank control sample was the solvent. The negative control sample was the cell culture. L929 cells were seeded into a 96-well plate at 8000 cells/well, and cultured overnight until the cells were adhered to the wall. After that, the culture medium was refreshed with 100 μL of sample solution, and the cells were cultured in a cell incubator at 37° C. with 5% CO.sub.2 and >90% humidity for 24 h. The test samples and the control sample were co-cultured with the cells. After 24 h, the cell activity was determined for each test concentration and compared to the cell activity of the negative control sample. The negative control group was 100% active. Changes in cell morphology due to cytotoxic effects of each sample were first observed and recorded after 24 h. The results showed that no change in cell morphology was caused by the different concentrations of the test samples. The medium was removed and 20 μL of 5 mg/mL MTT was added to each well and further incubated for 4 h. Then the MTT solution was discarded, and 100 μL of DMSO solution was added to each well. After the plate was shaken to mix well for 15 min, the absorbance at 490 nm was determined by a microplate reader. The results are shown in
[0265] The examples of the present disclosure have been described above. However, the present disclosure is not limited to the above examples. Any modification, equivalent, improvement and the like made without departing from the spirit and principle of the present disclosure shall fall within the protection scope of the present disclosure.